Abcam, ab249608, Anti-PDE4B antibody [EPR11830] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal PDE4B3 antibody. Carrier free. Suitable for WB, Flow Cyt (Intra) and reacts with Human, Mouse samples. Cited in 1 publication.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR11830,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Mouse, Human,
Applications:Flow Cyt (Intra), WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab249608 is the carrier-free version of
ab170939
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Phosphodiesterase 4B (PDE4B) also known as PDE4B2 is an enzyme that specifically breaks down cyclic adenosine monophosphate (cAMP) to AMP an important process in cellular signaling. It belongs to the PDE4 family which is characterized by its ability to regulate the concentration of cAMP within cells. PDE4B has a molecular mass of approximately 75 kDa and is frequently expressed in immune cells including monocytes and neutrophils as well as in the brain.
Biological function summary
PDE4B plays a significant role in modulating intracellular signaling by controlling the levels of cAMP a second messenger involved in various cellular processes. As part of the larger PDE4 family complex PDE4B assists in fine-tuning immune responses and inflammatory processes. This enzyme modulates the activity of protein kinase A (PKA) impacting processes such as cell proliferation differentiation and apoptosis.
Pathways
PDE4B operates within the cAMP signaling pathway which is essential for transducing extracellular signals into cellular responses. This pathway involves interaction with other proteins such as PKA and CREB (cAMP response element-binding protein) which are critical for regulating gene expression and cellular functions. PDE4B's ability to modulate this pathway makes it fundamental in controlling the dynamics of cellular signaling.
PDE4B has been associated with inflammatory diseases such as asthma and chronic obstructive pulmonary disease (COPD). Its involvement in regulating cAMP levels affects the inflammatory response linking it to the pathogenesis of these conditions. Additionally PDE4B influences the activity of inflammatory mediators and cytokines contributing to disease progression and symptoms. For example PDE4 inhibitors can modulate these pathways presenting potential therapeutic opportunities for managing related inflammatory disorders.